Our findings revealed that furin inhibition in CAR-Ms not only promotes the phagocytic activity of CAR-Ms against breast cancer cells but also maintains a pro-inflammatory phenotype in contact with cancer cells, which is critical for maintaining therapeutic efficacy over time. The gene discussed is FURIN; the disease is breast carcinoma.